

## **II. REMARKS**

### **Regarding the Sequence Listing**

In response to the to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated January 24, 2007 (provided herewith) Applicants submit an electronically readable form a sequence listing as a “.txt” text file in compliance with 37 C.F.R. § 1.821-1.825. Applicants also submit herein an amendment to the specification to comply with the sequence rules, and respectfully request its entry. Applicants also submit herewith a statement under 37 C.F.R. § 1.821(g).

### **Specification Amendment**

Applicants have amended the specification on page 1 to comply with the Sequence Listing requirements of 37 CFR 1.821 through 1.825. This amendment to the specification merely adds language to incorporate the Sequence Listing, and adds no new subject matter. Applicants respectfully request entry of this amendment.

### **Conclusion**

In view of the amendment and the above remarks, it is submitted that the application is in condition for allowance. The Examiner is invited to contact Applicants' undersigned representative if there are any questions relating to this application.

Respectfully submitted,

/Elizabeth A. Orr/

March 26, 2007

Elizabeth A. Orr  
Reg. No. 45,937  
(760) 476-7138

Invitrogen Corp.  
Customer Number: **52059**